failing? …Because it is limiting access to new medicines In the current system, when pharmaceutical companies develop new medicines, they receive patent protection for 20 years. This means they have a monopoly on those treatments, allowing them to charge extremely high prices, which restricts access to medicines, even in high-‐income countries. …Because it is not driven by health needs Research is profit-‐driven and does not meet the needs of the majority of the world's population. This is especially detrimental to the world's poor populations who have just 1% of research devoted to diseases that affect them. …Because it is not innovative In the past 10 years only 25% of the new medicines that were approved on the market provided a therapeutic benefit for patients (look it up, it is true! Revenue Prescrire, 2015). Innovation is lagging behind -‐ in the past 25 years it has never been as slow as it is today. …Because it is inefficient The current system prohibits sharing of knowledge between researchers, hindering scientific progress in the development of new medicines. This happens because when researchers don’t share their progress regularly a lot of research is duplicated. How a global Research & Development (R&D) agreement can change this? The World Health organisation is an agency of the United Nations (UN) that is concerned with international public health. The WHO, after recognising that the current system is failing and that we need an alternative, established an Expert Working Group in 2010. This group made a proposal for a global R&D agreement on funding and coordination of medical research and development. However, since 2012, the discussions were repeatedly postponed. We strongly believe an agreement at the WHO is key to a significant change in our flawed system and we cannot afford to postpone it any further. What a global R&D agreement should include: • A binding commitment of WHO Member States to ensure sustainable funding of R&D based on global health needs. • A commitment to use alternative mechanisms that do not rely on high prices to finance and incentivize innovation. • Provisions to encourage sharing of knowledge between researchers and across borders, enhancing the speed and efficiency of innovation. In 2016 the WHO must put an agreement back on the negotiating table. Join us in asking the WHO to: Make medicines for people not for profit -‐ negotiate a global R&D agreement now!
institutdelelevage
kobayashi31
enochan
ayatokanada
rfujii
hisaokatsumi
youten622
koide3
kentaitakura
rikkabotan7
resolutionfoundation
keathley
madoxten
3n
tammyeverts
addyosmani
maggiecrowley
soysaucechin
rkendrick25
aleyda
marcduiker
kastner
baasie
